FREE subscriptions for doctors and students... click here
You have 3 more open access pages.
Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder characterised by the arrest of differentiation of the progenitor cells (“blasts”) coupled with an accumulation of immature progenitors in the bone marrow, resulting in hematopoietic failure (1).
- AML is generally a disease of older adults - median age at diagnosis between
65 and 70 year of age
- after age 5-10, every year of age worsens the prognosis for patients with
- AML in older individuals is a more recalcitrant disease
- the disease tends to be less proliferative with average bone marrow
blast counts of 20% in those older than 60 and 40% in those younger than
60. When compared with those younger than 56, those older than 56 are
less likely to have favorable cytogenetics (16% vs. 5%) and more likely
to have unfavorable cytogenetics (33% vs. 50%)
Last reviewed 01/2018